| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis, Autoimmune | 21 | 2024 | 51 | 6.600 |
Why?
|
| Liver Cirrhosis, Biliary | 36 | 2024 | 78 | 5.150 |
Why?
|
| Hepacivirus | 42 | 2020 | 397 | 4.840 |
Why?
|
| Ribavirin | 30 | 2018 | 178 | 4.400 |
Why?
|
| Hepatitis C, Chronic | 33 | 2020 | 451 | 4.360 |
Why?
|
| Antiviral Agents | 40 | 2024 | 1230 | 4.060 |
Why?
|
| Interferon-alpha | 26 | 2016 | 889 | 3.080 |
Why?
|
| Liver Transplantation | 51 | 2021 | 1112 | 3.050 |
Why?
|
| Polyethylene Glycols | 23 | 2016 | 615 | 2.900 |
Why?
|
| Proline | 15 | 2018 | 130 | 2.290 |
Why?
|
| Hepatitis C | 17 | 2017 | 524 | 2.100 |
Why?
|
| Hepatitis B | 19 | 2024 | 258 | 2.090 |
Why?
|
| RNA, Viral | 26 | 2018 | 671 | 2.020 |
Why?
|
| Liver Cirrhosis | 18 | 2018 | 941 | 1.810 |
Why?
|
| Cholangitis | 13 | 2024 | 48 | 1.710 |
Why?
|
| Immunosuppressive Agents | 17 | 2024 | 1375 | 1.620 |
Why?
|
| Hepatic Encephalopathy | 9 | 2016 | 66 | 1.590 |
Why?
|
| Cholangitis, Sclerosing | 8 | 2024 | 77 | 1.520 |
Why?
|
| PPAR delta | 5 | 2024 | 55 | 1.260 |
Why?
|
| Hepatitis B virus | 12 | 2024 | 217 | 1.220 |
Why?
|
| Quinoxalines | 10 | 2020 | 95 | 1.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 9 | 2023 | 193 | 1.130 |
Why?
|
| Graft Rejection | 12 | 2020 | 834 | 1.130 |
Why?
|
| Tissue and Organ Procurement | 9 | 2021 | 233 | 1.000 |
Why?
|
| Imidazoles | 11 | 2020 | 999 | 0.980 |
Why?
|
| Terminology as Topic | 9 | 2015 | 414 | 0.980 |
Why?
|
| Liver | 33 | 2022 | 2961 | 0.960 |
Why?
|
| Hepatitis | 6 | 2022 | 93 | 0.930 |
Why?
|
| Drug Therapy, Combination | 29 | 2018 | 2315 | 0.890 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2023 | 421 | 0.860 |
Why?
|
| Viral Load | 13 | 2018 | 493 | 0.790 |
Why?
|
| Recombinant Proteins | 25 | 2016 | 2927 | 0.790 |
Why?
|
| Benzofurans | 5 | 2020 | 38 | 0.770 |
Why?
|
| Tissue Donors | 9 | 2021 | 769 | 0.760 |
Why?
|
| Liver Failure, Acute | 3 | 2011 | 88 | 0.750 |
Why?
|
| Carbamates | 14 | 2020 | 77 | 0.740 |
Why?
|
| Alkaline Phosphatase | 9 | 2024 | 207 | 0.730 |
Why?
|
| Organ Transplantation | 2 | 2020 | 191 | 0.720 |
Why?
|
| Ursodeoxycholic Acid | 11 | 2024 | 51 | 0.700 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 276 | 0.690 |
Why?
|
| Genotype | 25 | 2020 | 4109 | 0.690 |
Why?
|
| Acetates | 5 | 2024 | 105 | 0.690 |
Why?
|
| Humans | 190 | 2024 | 261506 | 0.680 |
Why?
|
| Ammonia | 2 | 2015 | 88 | 0.650 |
Why?
|
| Bile Ducts | 5 | 2011 | 113 | 0.650 |
Why?
|
| Cystatin C | 1 | 2018 | 54 | 0.630 |
Why?
|
| Sulfonamides | 12 | 2020 | 1823 | 0.570 |
Why?
|
| Autoimmune Diseases | 6 | 2019 | 402 | 0.570 |
Why?
|
| Automobile Driving | 1 | 2015 | 29 | 0.530 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 3203 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 602 | 0.520 |
Why?
|
| Liability, Legal | 1 | 2015 | 48 | 0.520 |
Why?
|
| Adult | 88 | 2023 | 77950 | 0.510 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 321 | 0.500 |
Why?
|
| Cyclopropanes | 10 | 2020 | 88 | 0.490 |
Why?
|
| DNA, Viral | 8 | 2015 | 694 | 0.480 |
Why?
|
| Virus Physiological Phenomena | 1 | 2014 | 19 | 0.480 |
Why?
|
| Drug Resistance, Viral | 7 | 2018 | 71 | 0.460 |
Why?
|
| Double-Blind Method | 16 | 2024 | 2588 | 0.450 |
Why?
|
| Gastrointestinal Agents | 2 | 2024 | 108 | 0.450 |
Why?
|
| Chalcones | 2 | 2023 | 7 | 0.440 |
Why?
|
| Middle Aged | 80 | 2022 | 86204 | 0.440 |
Why?
|
| Liver Failure | 4 | 2017 | 140 | 0.430 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2011 | 673 | 0.430 |
Why?
|
| Propionates | 2 | 2023 | 71 | 0.430 |
Why?
|
| Graft vs Host Disease | 8 | 2011 | 2638 | 0.410 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 148 | 0.400 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 43 | 0.380 |
Why?
|
| Amides | 7 | 2020 | 123 | 0.380 |
Why?
|
| Male | 87 | 2023 | 123000 | 0.380 |
Why?
|
| Autoantibodies | 8 | 2018 | 576 | 0.380 |
Why?
|
| Sofosbuvir | 4 | 2018 | 22 | 0.360 |
Why?
|
| Female | 88 | 2023 | 141928 | 0.360 |
Why?
|
| Drug Overdose | 3 | 2020 | 81 | 0.350 |
Why?
|
| Autoantigens | 1 | 2011 | 234 | 0.350 |
Why?
|
| HIV | 1 | 2011 | 229 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2015 | 786 | 0.350 |
Why?
|
| Aged | 48 | 2022 | 70117 | 0.340 |
Why?
|
| Transplant Recipients | 3 | 2021 | 324 | 0.330 |
Why?
|
| Hypertension, Portal | 4 | 2014 | 124 | 0.330 |
Why?
|
| Community Health Services | 1 | 2010 | 126 | 0.330 |
Why?
|
| Interferons | 6 | 2014 | 291 | 0.330 |
Why?
|
| Mass Screening | 5 | 2019 | 1509 | 0.320 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 4320 | 0.320 |
Why?
|
| Cholagogues and Choleretics | 6 | 2024 | 33 | 0.320 |
Why?
|
| Viral Nonstructural Proteins | 5 | 2018 | 163 | 0.320 |
Why?
|
| Treatment Outcome | 32 | 2024 | 32848 | 0.310 |
Why?
|
| Pruritus | 6 | 2024 | 87 | 0.310 |
Why?
|
| Immunoglobulins | 4 | 2005 | 266 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 1993 | 334 | 0.290 |
Why?
|
| Physicians | 1 | 2015 | 882 | 0.290 |
Why?
|
| Insulin Resistance | 1 | 2012 | 731 | 0.280 |
Why?
|
| Epithelial Cells | 4 | 2011 | 1818 | 0.280 |
Why?
|
| Oligopeptides | 3 | 2014 | 429 | 0.280 |
Why?
|
| Hepatitis B, Chronic | 1 | 2007 | 137 | 0.280 |
Why?
|
| Adolescent | 32 | 2023 | 31252 | 0.270 |
Why?
|
| Young Adult | 21 | 2022 | 21445 | 0.270 |
Why?
|
| Biliary Tract Diseases | 2 | 1999 | 61 | 0.260 |
Why?
|
| Cholestasis | 3 | 2023 | 203 | 0.260 |
Why?
|
| Isoquinolines | 2 | 2015 | 116 | 0.250 |
Why?
|
| PPAR alpha | 2 | 2023 | 62 | 0.250 |
Why?
|
| Interleukins | 5 | 2014 | 325 | 0.250 |
Why?
|
| Hepatitis B Antibodies | 6 | 2012 | 58 | 0.240 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2023 | 25 | 0.240 |
Why?
|
| Referral and Consultation | 1 | 2010 | 899 | 0.240 |
Why?
|
| Virus Activation | 4 | 2024 | 228 | 0.240 |
Why?
|
| Risk Factors | 16 | 2021 | 17523 | 0.240 |
Why?
|
| Pyrrolidines | 7 | 2018 | 113 | 0.240 |
Why?
|
| Iron Overload | 1 | 2023 | 35 | 0.230 |
Why?
|
| Hemochromatosis | 1 | 2023 | 35 | 0.230 |
Why?
|
| HIV Infections | 3 | 2018 | 2134 | 0.230 |
Why?
|
| Hepatitis B Antigens | 4 | 2010 | 15 | 0.230 |
Why?
|
| Liver Diseases | 7 | 2007 | 574 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 7 | 2012 | 84 | 0.220 |
Why?
|
| Transaminases | 3 | 2022 | 76 | 0.220 |
Why?
|
| Antibodies, Antinuclear | 2 | 2019 | 46 | 0.220 |
Why?
|
| Bilirubin | 6 | 2024 | 221 | 0.220 |
Why?
|
| Biomarkers | 10 | 2023 | 5047 | 0.220 |
Why?
|
| Immunization | 2 | 2024 | 397 | 0.210 |
Why?
|
| Cyclosporine | 4 | 2016 | 278 | 0.210 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.210 |
Why?
|
| Biopsy | 8 | 2022 | 3443 | 0.210 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2021 | 171 | 0.200 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 538 | 0.200 |
Why?
|
| Gilbert Disease | 4 | 2013 | 5 | 0.200 |
Why?
|
| Plasma Cells | 1 | 2022 | 192 | 0.200 |
Why?
|
| Sex Factors | 2 | 2018 | 2139 | 0.200 |
Why?
|
| Valine | 6 | 2018 | 176 | 0.200 |
Why?
|
| Data Collection | 1 | 2024 | 620 | 0.200 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 755 | 0.190 |
Why?
|
| Donor Selection | 2 | 2019 | 110 | 0.190 |
Why?
|
| Retrospective Studies | 23 | 2021 | 37905 | 0.190 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 187 | 0.190 |
Why?
|
| Graft Survival | 6 | 2021 | 1062 | 0.190 |
Why?
|
| Living Donors | 4 | 2021 | 171 | 0.190 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 3719 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2017 | 1171 | 0.190 |
Why?
|
| Cystic Fibrosis | 3 | 2020 | 264 | 0.180 |
Why?
|
| Waiting Lists | 4 | 2020 | 263 | 0.180 |
Why?
|
| Learning Curve | 1 | 2020 | 68 | 0.180 |
Why?
|
| Recurrence | 10 | 2018 | 4758 | 0.180 |
Why?
|
| Transplantation | 1 | 2019 | 56 | 0.180 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2017 | 119 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 447 | 0.170 |
Why?
|
| HLA Antigens | 4 | 2016 | 546 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2018 | 1391 | 0.170 |
Why?
|
| T-Lymphocytes | 9 | 2012 | 3869 | 0.170 |
Why?
|
| Health Facilities | 1 | 2019 | 79 | 0.170 |
Why?
|
| Fibrosis | 1 | 2022 | 793 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 6 | 2011 | 2314 | 0.160 |
Why?
|
| Drug Combinations | 5 | 2018 | 621 | 0.160 |
Why?
|
| Protease Inhibitors | 3 | 2017 | 210 | 0.160 |
Why?
|
| Allografts | 4 | 2021 | 650 | 0.160 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 3472 | 0.160 |
Why?
|
| Suicide | 1 | 2020 | 180 | 0.150 |
Why?
|
| Immunization, Passive | 4 | 2000 | 172 | 0.150 |
Why?
|
| Macrocyclic Compounds | 1 | 2017 | 10 | 0.150 |
Why?
|
| Vaccination | 1 | 2024 | 1123 | 0.150 |
Why?
|
| Sustained Virologic Response | 4 | 2018 | 57 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2013 | 1353 | 0.150 |
Why?
|
| Uridine | 1 | 2017 | 59 | 0.150 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1994 | 58 | 0.150 |
Why?
|
| Glycerol | 2 | 2014 | 99 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1991 | 709 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 1489 | 0.150 |
Why?
|
| Administration, Oral | 5 | 2024 | 1544 | 0.150 |
Why?
|
| Disease Progression | 6 | 2022 | 6682 | 0.140 |
Why?
|
| Phenylbutyrates | 2 | 2014 | 59 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2018 | 6869 | 0.140 |
Why?
|
| Liver Neoplasms | 7 | 2014 | 4557 | 0.140 |
Why?
|
| Narcotics | 1 | 2017 | 123 | 0.140 |
Why?
|
| Spleen | 4 | 2011 | 676 | 0.140 |
Why?
|
| Acetaminophen | 2 | 2013 | 116 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2007 | 9180 | 0.140 |
Why?
|
| Transplantation, Homologous | 6 | 2007 | 2843 | 0.140 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2020 | 359 | 0.140 |
Why?
|
| Creatinine | 1 | 2018 | 531 | 0.130 |
Why?
|
| Biological Products | 1 | 2019 | 274 | 0.130 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 24 | 0.130 |
Why?
|
| Bile Duct Diseases | 2 | 1993 | 45 | 0.130 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1995 | 12 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2012 | 27 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 462 | 0.130 |
Why?
|
| Geography | 1 | 2015 | 140 | 0.130 |
Why?
|
| Prevalence | 2 | 2022 | 3260 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2015 | 185 | 0.130 |
Why?
|
| Fasting | 2 | 2015 | 349 | 0.130 |
Why?
|
| Glutamine | 2 | 2014 | 299 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 116 | 0.130 |
Why?
|
| Prognosis | 9 | 2020 | 21713 | 0.130 |
Why?
|
| Lactams | 1 | 2014 | 24 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 108 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2018 | 428 | 0.120 |
Why?
|
| Confidentiality | 1 | 2015 | 127 | 0.120 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1994 | 48 | 0.120 |
Why?
|
| Tacrolimus | 4 | 2021 | 335 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2014 | 2027 | 0.120 |
Why?
|
| Thioguanine | 2 | 2004 | 68 | 0.120 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2014 | 20 | 0.120 |
Why?
|
| Metabolomics | 1 | 2017 | 478 | 0.120 |
Why?
|
| Ritonavir | 1 | 2014 | 67 | 0.120 |
Why?
|
| Phenylacetates | 1 | 2013 | 20 | 0.120 |
Why?
|
| Congresses as Topic | 3 | 2023 | 298 | 0.120 |
Why?
|
| Hyperammonemia | 1 | 2014 | 68 | 0.120 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 423 | 0.120 |
Why?
|
| Secondary Prevention | 4 | 2000 | 329 | 0.120 |
Why?
|
| Minor Histocompatibility Loci | 2 | 1991 | 4 | 0.120 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 62 | 0.120 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1993 | 97 | 0.110 |
Why?
|
| Uridine Monophosphate | 1 | 2013 | 18 | 0.110 |
Why?
|
| Liver Function Tests | 6 | 2020 | 173 | 0.110 |
Why?
|
| Caffeine | 1 | 2013 | 87 | 0.110 |
Why?
|
| Azathioprine | 3 | 2018 | 66 | 0.110 |
Why?
|
| Immunologic Factors | 2 | 2020 | 649 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 622 | 0.110 |
Why?
|
| Limit of Detection | 1 | 2013 | 78 | 0.110 |
Why?
|
| Liver, Artificial | 2 | 2011 | 8 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 617 | 0.110 |
Why?
|
| Chronic Disease | 8 | 1999 | 1819 | 0.110 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2013 | 80 | 0.110 |
Why?
|
| Medical Futility | 1 | 2013 | 54 | 0.110 |
Why?
|
| RNA Probes | 1 | 1992 | 44 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2005 | 3341 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 3 | 2018 | 90 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 260 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 336 | 0.100 |
Why?
|
| Cytokines | 4 | 2011 | 2809 | 0.100 |
Why?
|
| Cyclophilins | 1 | 2011 | 32 | 0.100 |
Why?
|
| Child | 14 | 2021 | 29154 | 0.100 |
Why?
|
| Hepatitis C Antibodies | 2 | 2010 | 41 | 0.100 |
Why?
|
| Contraindications | 2 | 2006 | 150 | 0.100 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 14889 | 0.100 |
Why?
|
| Self Tolerance | 1 | 2011 | 18 | 0.100 |
Why?
|
| Quality of Life | 6 | 2021 | 4532 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 630 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 644 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 184 | 0.100 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2011 | 60 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1900 | 0.100 |
Why?
|
| United States | 11 | 2017 | 15433 | 0.090 |
Why?
|
| Postoperative Complications | 5 | 2020 | 5542 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 157 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 394 | 0.090 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2008 | 74 | 0.090 |
Why?
|
| Viral Structural Proteins | 1 | 1990 | 47 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2594 | 0.090 |
Why?
|
| Aspirin | 1 | 2013 | 455 | 0.090 |
Why?
|
| Animals | 20 | 2020 | 59536 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 521 | 0.090 |
Why?
|
| Genes, Viral | 1 | 1990 | 202 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 1992 | 577 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2007 | 4971 | 0.090 |
Why?
|
| Cell Movement | 2 | 2005 | 2466 | 0.090 |
Why?
|
| Survival Rate | 4 | 2019 | 12221 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 3441 | 0.090 |
Why?
|
| Immune Tolerance | 2 | 2007 | 403 | 0.090 |
Why?
|
| Indoles | 1 | 2015 | 1009 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 314 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2011 | 1688 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 363 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 864 | 0.090 |
Why?
|
| Copper | 2 | 1981 | 165 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 317 | 0.080 |
Why?
|
| Neoplasms | 7 | 2020 | 15193 | 0.080 |
Why?
|
| Time Factors | 11 | 2019 | 12926 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 884 | 0.080 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 4744 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 2146 | 0.080 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 268 | 0.080 |
Why?
|
| Base Sequence | 5 | 1998 | 4917 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 558 | 0.080 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 9 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 1998 | 6089 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 586 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 1581 | 0.080 |
Why?
|
| United Kingdom | 2 | 2019 | 257 | 0.080 |
Why?
|
| Hyperbilirubinemia, Hereditary | 3 | 1982 | 3 | 0.080 |
Why?
|
| Chylous Ascites | 1 | 1987 | 25 | 0.080 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 1987 | 8 | 0.080 |
Why?
|
| Insemination, Artificial | 1 | 1987 | 12 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4892 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 249 | 0.070 |
Why?
|
| Rituximab | 3 | 2020 | 1528 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2013 | 598 | 0.070 |
Why?
|
| Prednisolone | 2 | 2018 | 123 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2012 | 6150 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 168 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 4938 | 0.070 |
Why?
|
| Interferon-gamma | 3 | 1999 | 1144 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 1987 | 128 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 85 | 0.070 |
Why?
|
| Trans-Activators | 1 | 1992 | 1555 | 0.070 |
Why?
|
| Epoprostenol | 1 | 2006 | 75 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5061 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1999 | 221 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 1294 | 0.070 |
Why?
|
| Leucine | 2 | 2018 | 352 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 1033 | 0.070 |
Why?
|
| Mice | 9 | 2011 | 34495 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1085 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 1429 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 29902 | 0.070 |
Why?
|
| Abdomen | 1 | 1987 | 332 | 0.070 |
Why?
|
| Puerto Rico | 2 | 2016 | 65 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 665 | 0.060 |
Why?
|
| Texas | 2 | 2021 | 6311 | 0.060 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 110 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 7789 | 0.060 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2004 | 12 | 0.060 |
Why?
|
| Risk Management | 1 | 2005 | 107 | 0.060 |
Why?
|
| 1-Naphthylisothiocyanate | 1 | 2004 | 4 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 552 | 0.060 |
Why?
|
| Cell Separation | 3 | 1992 | 612 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2011 | 1085 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.060 |
Why?
|
| Coinfection | 2 | 2018 | 189 | 0.060 |
Why?
|
| Macrophages | 1 | 1991 | 1304 | 0.060 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 1997 | 56 | 0.060 |
Why?
|
| Hepatitis A | 2 | 2013 | 32 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3639 | 0.060 |
Why?
|
| Transferrins | 1 | 2023 | 2 | 0.060 |
Why?
|
| Muromonab-CD3 | 1 | 2003 | 19 | 0.060 |
Why?
|
| Skin Diseases | 1 | 1987 | 349 | 0.060 |
Why?
|
| Hemochromatosis Protein | 1 | 2023 | 23 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 235 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2005 | 717 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 117 | 0.060 |
Why?
|
| Remission Induction | 4 | 2018 | 3569 | 0.060 |
Why?
|
| Hepcidins | 1 | 2023 | 34 | 0.060 |
Why?
|
| Nitrofurantoin | 1 | 2023 | 8 | 0.060 |
Why?
|
| Acute Disease | 3 | 1999 | 2422 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2005 | 263 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 395 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 1586 | 0.060 |
Why?
|
| Drug Carriers | 2 | 2015 | 327 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2007 | 677 | 0.060 |
Why?
|
| Ferritins | 1 | 2023 | 151 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 419 | 0.060 |
Why?
|
| Retreatment | 2 | 2016 | 452 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 7222 | 0.060 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 1999 | 5637 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2023 | 94 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2023 | 90 | 0.050 |
Why?
|
| Cholic Acids | 1 | 1982 | 30 | 0.050 |
Why?
|
| Ceruloplasmin | 2 | 1981 | 35 | 0.050 |
Why?
|
| Nausea | 2 | 2017 | 525 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 235 | 0.050 |
Why?
|
| Gastroenterology | 1 | 2005 | 195 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1362 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2011 | 16273 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 2 | 1992 | 91 | 0.050 |
Why?
|
| Lamivudine | 1 | 2001 | 28 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 51 | 0.050 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 1618 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1994 | 1213 | 0.050 |
Why?
|
| Infant | 5 | 2011 | 13310 | 0.050 |
Why?
|
| Isoantigens | 2 | 1992 | 62 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2004 | 351 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 2796 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2022 | 12873 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2019 | 785 | 0.050 |
Why?
|
| Hepatitis Antigens | 1 | 2000 | 1 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 376 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 4314 | 0.050 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2019 | 21 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 441 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2000 | 51 | 0.040 |
Why?
|
| Sirolimus | 1 | 2004 | 814 | 0.040 |
Why?
|
| Carbonic Anhydrases | 1 | 1999 | 44 | 0.040 |
Why?
|
| Epidemics | 1 | 2020 | 63 | 0.040 |
Why?
|
| Abatacept | 1 | 2019 | 26 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 74 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 1082 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 333 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 88 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 4053 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 574 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 1999 | 138 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2005 | 1011 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 1999 | 137 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1992 | 582 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 178 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5159 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1998 | 32 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 544 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5539 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 945 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8223 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2018 | 72 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 226 | 0.040 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1978 | 44 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 1879 | 0.040 |
Why?
|
| Epithelium | 2 | 1993 | 720 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 366 | 0.040 |
Why?
|
| Radioisotopes | 1 | 1978 | 177 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 1303 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 1756 | 0.040 |
Why?
|
| Medicaid | 1 | 2000 | 279 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1998 | 829 | 0.040 |
Why?
|
| Budesonide | 1 | 2016 | 34 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 227 | 0.040 |
Why?
|
| Taiwan | 1 | 2016 | 93 | 0.040 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 27 | 0.040 |
Why?
|
| Rats | 4 | 2008 | 6086 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1981 | 675 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 245 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2008 | 7226 | 0.040 |
Why?
|
| Asia | 1 | 2016 | 142 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 3890 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 227 | 0.030 |
Why?
|
| Transfection | 2 | 1992 | 2944 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 148 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6009 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 1995 | 14 | 0.030 |
Why?
|
| Rifamycins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Piperazines | 1 | 2005 | 2101 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2000 | 739 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 340 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 752 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 2004 | 684 | 0.030 |
Why?
|
| Morbidity | 1 | 1997 | 397 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2014 | 9244 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2016 | 148 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 170 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 430 | 0.030 |
Why?
|
| Nutrition Surveys | 2 | 2007 | 295 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 154 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Monocytes | 2 | 1992 | 788 | 0.030 |
Why?
|
| Isoindoles | 1 | 2014 | 11 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 1021 | 0.030 |
Why?
|
| Hepatitis D | 1 | 1994 | 4 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1994 | 7 | 0.030 |
Why?
|
| Medicare | 1 | 2000 | 860 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 1994 | 7 | 0.030 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1995 | 39 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1998 | 465 | 0.030 |
Why?
|
| Hepatitis E | 1 | 1994 | 9 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 29 | 0.030 |
Why?
|
| Ligases | 1 | 1994 | 70 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 216 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 960 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2004 | 600 | 0.030 |
Why?
|
| Magnesium Chloride | 1 | 1993 | 3 | 0.030 |
Why?
|
| Mitogens | 2 | 1992 | 75 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 1993 | 13 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1993 | 48 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1993 | 34 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 130 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1994 | 542 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2014 | 107 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8865 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1995 | 471 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 204 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1994 | 176 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 285 | 0.030 |
Why?
|
| Quality Control | 1 | 1994 | 457 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 492 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 249 | 0.030 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.030 |
Why?
|
| Portal Vein | 1 | 1995 | 355 | 0.030 |
Why?
|
| Thiazoles | 1 | 2017 | 726 | 0.030 |
Why?
|
| Bile | 2 | 2004 | 81 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 219 | 0.030 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1992 | 64 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 717 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 290 | 0.030 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1992 | 16 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1995 | 234 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 1282 | 0.030 |
Why?
|
| Reoperation | 1 | 1997 | 1382 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1993 | 182 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 1997 | 524 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2005 | 3518 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 429 | 0.030 |
Why?
|
| Indomethacin | 1 | 1992 | 91 | 0.030 |
Why?
|
| Virus Replication | 1 | 1995 | 709 | 0.030 |
Why?
|
| Necrosis | 1 | 1993 | 580 | 0.030 |
Why?
|
| Genes | 1 | 1992 | 491 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 437 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1992 | 682 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1994 | 731 | 0.030 |
Why?
|
| Lymphocytes, Null | 1 | 1991 | 5 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 297 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 182 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.020 |
Why?
|
| Introns | 1 | 1992 | 432 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1991 | 182 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1992 | 235 | 0.020 |
Why?
|
| Ischemia | 1 | 1993 | 391 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 499 | 0.020 |
Why?
|
| Plastics | 1 | 1991 | 93 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 521 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 435 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2006 | 1529 | 0.020 |
Why?
|
| Autoradiography | 1 | 1989 | 132 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1993 | 442 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1990 | 112 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1990 | 284 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 489 | 0.020 |
Why?
|
| Indocyanine Green | 2 | 1982 | 117 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.020 |
Why?
|
| Antibodies | 1 | 1992 | 838 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 224 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 7548 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 193 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1989 | 699 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 2489 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 1062 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 133 | 0.020 |
Why?
|
| Hepatitis B e Antigens | 1 | 1987 | 10 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1681 | 0.020 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1990 | 261 | 0.020 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2006 | 10 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2007 | 6100 | 0.020 |
Why?
|
| Epitopes | 1 | 1989 | 685 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2007 | 77 | 0.020 |
Why?
|
| Government Regulation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Peritoneum | 1 | 1987 | 150 | 0.020 |
Why?
|
| Semen | 1 | 1987 | 90 | 0.020 |
Why?
|
| Social Justice | 1 | 2007 | 61 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1985 | 14 | 0.020 |
Why?
|
| Bile Canaliculi | 1 | 1985 | 6 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1995 | 1225 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 198 | 0.020 |
Why?
|
| Microvilli | 1 | 1985 | 83 | 0.020 |
Why?
|
| California | 1 | 2006 | 208 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1985 | 138 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 689 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 5395 | 0.020 |
Why?
|
| Sulfobromophthalein | 2 | 1982 | 4 | 0.020 |
Why?
|
| Reproductive Medicine | 1 | 2005 | 50 | 0.020 |
Why?
|
| Anthropometry | 1 | 2005 | 269 | 0.020 |
Why?
|
| Hydroxyproline | 1 | 2004 | 9 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 3154 | 0.020 |
Why?
|
| Demography | 1 | 2005 | 435 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6207 | 0.020 |
Why?
|
| Medical Records | 1 | 2005 | 415 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 1239 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2005 | 497 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1990 | 3033 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 5687 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 1382 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1984 | 208 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1990 | 1682 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 2 | 1981 | 12 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 1323 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1982 | 191 | 0.010 |
Why?
|
| Cell Line | 1 | 1990 | 5114 | 0.010 |
Why?
|
| Penicillamine | 1 | 1981 | 22 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 612 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 557 | 0.010 |
Why?
|
| Spherocytosis, Hereditary | 1 | 1981 | 8 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2006 | 493 | 0.010 |
Why?
|
| Thyroxine | 1 | 1981 | 116 | 0.010 |
Why?
|
| Kinetics | 2 | 1982 | 2049 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1983 | 553 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1981 | 211 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 125 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 2292 | 0.010 |
Why?
|
| Splenectomy | 1 | 1981 | 158 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 1665 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1983 | 289 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1467 | 0.010 |
Why?
|
| Reference Values | 1 | 1982 | 1099 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1981 | 875 | 0.010 |
Why?
|
| Neutrophils | 1 | 2004 | 835 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4298 | 0.010 |
Why?
|
| Benzamides | 1 | 2005 | 1832 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1979 | 48 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 7551 | 0.010 |
Why?
|
| Complement C3b | 1 | 1978 | 10 | 0.010 |
Why?
|
| Animal Rights | 1 | 1998 | 2 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1998 | 27 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 7702 | 0.010 |
Why?
|
| Haplorhini | 1 | 1998 | 130 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1998 | 44 | 0.010 |
Why?
|
| Vascular Fistula | 1 | 1998 | 41 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1977 | 57 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2203 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1977 | 84 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1977 | 84 | 0.010 |
Why?
|
| Trypsin | 1 | 1977 | 140 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1977 | 68 | 0.010 |
Why?
|
| Mutation | 1 | 1998 | 15179 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1977 | 47 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1998 | 178 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1998 | 152 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 3254 | 0.010 |
Why?
|
| Temperance | 1 | 1997 | 16 | 0.010 |
Why?
|
| Estrogens | 1 | 1981 | 751 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1998 | 240 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 587 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1978 | 573 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1985 | 2022 | 0.010 |
Why?
|
| Testosterone | 1 | 1981 | 619 | 0.010 |
Why?
|
| Consciousness | 1 | 1997 | 56 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 1155 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 159 | 0.010 |
Why?
|
| Homeostasis | 1 | 1981 | 950 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1987 | 2967 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1977 | 171 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2403 | 0.010 |
Why?
|
| Eosinophils | 1 | 1997 | 162 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1998 | 206 | 0.010 |
Why?
|
| Prednisone | 1 | 1999 | 984 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1998 | 375 | 0.010 |
Why?
|
| Intracranial Pressure | 1 | 1997 | 180 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 31 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1999 | 629 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1998 | 442 | 0.010 |
Why?
|
| Alcoholism | 1 | 1997 | 285 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 5710 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1997 | 551 | 0.010 |
Why?
|
| Diet | 1 | 1981 | 1440 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1995 | 980 | 0.010 |
Why?
|
| Equipment Design | 1 | 1997 | 1204 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 1541 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1997 | 935 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1977 | 1234 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 4233 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 2307 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 1904 | 0.010 |
Why?
|
| Comorbidity | 1 | 1997 | 2352 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 2803 | 0.010 |
Why?
|
| Biological Transport | 2 | 1979 | 597 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1981 | 49 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1981 | 115 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1981 | 104 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1981 | 139 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1981 | 295 | 0.000 |
Why?
|
| Antigens | 1 | 1981 | 292 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1981 | 383 | 0.000 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1978 | 44 | 0.000 |
Why?
|
| Glucagon | 1 | 1979 | 196 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1979 | 97 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1978 | 231 | 0.000 |
Why?
|
| Hematinics | 1 | 1979 | 109 | 0.000 |
Why?
|
| Lipoproteins | 1 | 1979 | 252 | 0.000 |
Why?
|
| Rabbits | 1 | 1979 | 957 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1981 | 904 | 0.000 |
Why?
|
| Glucuronosyltransferase | 1 | 1976 | 104 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1979 | 850 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1979 | 747 | 0.000 |
Why?
|
| Binding Sites | 1 | 1978 | 2171 | 0.000 |
Why?
|